Clopidogrel Monotherapy in Patients With High Bleeding Risk
Status:
Not yet recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
The goal of this research is to show that a shorter duration of two antiplatelet medications
(compared to the standard of care) is safe and effective while reducing the risk of bleeding
complications. Bleeding complications can cause significant problems (hospitalizations, need
for blood transfusions, and even death) for patients on antiplatelet medications after
coronary stents. Researchers hope to show that reducing the time on two antiplatelet agents
in patients at high risk for these bleeding complications will reduce the number of bleeding
events while not causing any increase in cardiovascular complications (heart attack, stent
malfunction, death).